The fight continues to gain access to the cystic fibrosis drugs Orkambi and Symkevi, as well as other treatments in the pipeline. Here we take a look at the current CFTR modulator drug pipeline, to see what the future might hold.
NHS England has today announced that people with cystic fibrosis (CF) living in England who stand to benefit from life-saving drugs Orkambi and Symkevi will receive them as part of a two-year managed access agreement with the manufacturer, Vertex Pharmaceuticals.
Find out how cystic fibrosis affects bone health and learn about the different types of bone disease that people with CF can experience. We also explore how low bone mineral density can be treated.
Lynsey Beswick, Public Affairs Manager at Cystic Fibrosis Trust, gives an update on the fight for access to medicines for people with cystic fibrosis (CF) in Scotland. Read on to find out more about the Peer Approved Clinical System and an upcoming Ultra Orphan Status decision.
At the end of a busy week of activity in the fight to stop the clock on cystic fibrosis, and on the eve of another, our Chief Executive, David Ramsden, shares his thoughts on where things stand.
Yesterday, Trust representatives met with the Pharmacy and Medicines Division of Scottish Government in Edinburgh to discuss Orkambi and new medicines. Meanwhile in Westminster, the Trust met with Matt Hancock MP, Secretary of State for Health and Social Care, to talk about the Government’s position in future negotiations for Orkambi and other treatments. Hear what our team learned from their meetings.